Skip to content

Gilbert is open for collaboration!

Gilbert is open for collaboration to redefine treatments for lung patients with an initial interest in improving inhaled anti-infective treatments.

Following our recent introduction at the SMI.London Conference on June 25th, we extend an invitation to Pharma, Biotech and Academia to collaborate and explore how electrospray can improve your inhaled therapy.  The Gilbert team will work with you to optimize formulation and electrospray aerosol generation in our dedicated lab to ensure you reach your target.

Download our latest brochure ‘What’s your target?’ to learn more.

The brochure elaborates on the need for precision in pulmonary drug delivery, and the important role particle size and particle size distribution play. It presents how electrospray produces monodisperse droplets with customizable droplet size, enabling more precise targeting in the lungs. It also describes the unique Features & Benefits of the Gilbert Smart Precision Inhaler under development.

Interested to explore? Please contact us at info@gilbert.eu.

Gilbert is developing the next generation of soft mist inhalers based on a proprietary electrospray (Electro Hydrodynamic Atomization or EHDA) technology to redefine treatment for lung patients. Gilbert’s breath actuated smart precision inhaler creates a monodispersed soft mist aerosol, with a customizable droplet size enabling more precise targeting of drugs to desired regions of the lungs, which has the potential to improve the efficacy and safety of treatments. Electrospray enables gentle, efficient delivery of both small and large molecule therapies in both solution and suspension formulations.

Visit us at Gilbert | Redefining treatment for lung patients, follow us on Linkedin or contact us at info@gilbert.eu to learn if electrospray is suitable for your application.

Other posts

Let’s stay in touch!

Stay up-to-date with Gilbert’s latest news, vacancies and achievements by following us on social media.